UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
OMB APPROVAL
OMB Number:3235-0080
Expires:February 28, 2009
Estimated average burden
hours per response:1.7

Commission File Number 001-38485
Issuer:Amneal Pharmaceuticals, Inc.
Exchange:NEW YORK STOCK EXCHANGE LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address:400 Cross Boulevard
BridgewaterNEW JERSEY08807
Telephone number:+1.510.240.6000
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Class A Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
☐ 17 CFR 240.12d2-2(a)(1)
☐17 CFR 240.12d2-2(a)(2)
☒17 CFR 240.12d2-2(a)(3)
☐17 CFR 240.12d2-2(a)(4)
☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
☐ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2023-11-08ByVictoria PaperManager, Market Watch and Proxy Compliance
DateNameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 20, 2023, pursuant to the provisions of Rule 12d2-2 (a). [ X ] 17 CFR 240.12d2-2(a)(3) That on November 07, 2023, the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment. Pursuant to the formation of a holding company which became effective on November 07, 2023, each share of Class A Common Stock of Amneal Pharmaceuticals, Inc. (Old) was converted automatically into one (1) share of Amneal Pharmaceuticals, Inc. (New) Class A Common Stock on a share for share basis. This Form 25 only for the removal from listing on the Exchange of the Class A Common Stock of Amneal Pharmaceuticals, Inc. (Old), and not a termination of the registration of the Class A Common Stock of Amneal Pharmaceuticals, Inc. (New) under Section 12(b) of the Exchange Act. The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions Amneal Pharmaceuticals, Inc. (Old) was suspended from trading on November 07, 2023.